Skip to main content
Premium Trial:

Request an Annual Quote

Second SARS-CoV-2 Vaccine Authorized in US

The US Food and Drug Administration granted on Friday an Emergency Use Authorization for Moderna's SARS-CoV-2 vaccine, the New York Times reports. This, it adds, is the second SARS-CoV-2 vaccine to receive authorization in the US, as one from Pfizer and BioNTech was authorized a week earlier.

Last month, Moderna announced that its mRNA-based vaccine had an efficacy of 94.5 percent and, last week, a briefing report from the FDA suggested the agency was in favor of authorizing the vaccine and an advisory panel to the FDA then voted in favor of doing so. The EUA came shortly thereafter.

"With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day," FDA Commissioner Stephen Hahn says in a statement.

The Times adds that the authorization has spurred the distribution of 5.9 million doses of the vaccine, the delivery of which will be managed by the federal government under Operation Warp Speed.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.